Prevention of erythropoietin-associated hypertension

Hypertension

Volumn 50, Issue 2, 2007, Pages 439-445

  Lee, Mary S ^a   Lee, John S ^b   Lee, Jong Y ^b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c NONE   (United States)

Author keywords

Cardiovascular parameters; Circadian effects; Erythropoiesis; Erythropoietin binding protein; Hypertension; Splenomegaly

Indexed keywords

BINDING PROTEIN; ERYTHROPOIETIN; ERYTHROPOIETIN ANTIBODY; ERYTHROPOIETIN BINDING PROTEIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; BRAIN WEIGHT; CONTROLLED STUDY; DRUG EFFECT; GENETIC ENGINEERING; HEART WEIGHT; HEMATOCRIT; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD PRESSURE DETERMINATION; BODY WEIGHT; CIRCADIAN RHYTHM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; ERYTHROPOIESIS; HEMATOCRIT; HYPERTENSION; PROBABILITY; PROTEIN BINDING; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE VALUES; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 34547617317     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.090423     Document Type: Article

References (53)

1. Fisher JW. Erythropoietin: physiologic and pharmacologic aspects. Proc Soc Exp Biol Med. 1997;216:358-369.
2. Krant SB. Erythropoietin Blood. 1991;77:419-439.
3. Mayeux P, Billat C, Jacquot R. The erythropoietin receptor of rat erythroid progenitor cells. Characterization and affinity cross-linkage. J Biol Chem. 1987;262:13985-13990.
4. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci U S A. 1990;87:6934-6938.
5. D'Andrea AD, Zon LI. Erythropoietin receptor: subunit structure and activation. J Clin Invest. 1990;86:681-687.
6. Dunbar CE, Browder TM, Abrams JS, Nienhuis AW. COOH-terminal-modified interleukin-3 is retained intracellularly and stimulates autocrine growth. Science. 1989;245:1493-1496.
7. Cull V, Tilbrook PA, Adenan AS, Chappell D, Ingley E, Sarna MK, Palmer TN, Watowich SS, Klinken SP. Dominant action of mutated erythropoietin receptors on differentiation in vitro and erythroleukemia development in vivo. Oncogene. 2000;19:953-960.
8. Fujita M, Takahashi R, Kitada K, Watanabe R, Kitazawa S, Ashoori F, Liang P, Saya H, Serikawa T, Maeda S. Alterative splicing of the erythropoietin receptor gene correlates with erythroid differentiation in rat hematopoietic and leukemic cells. Cancer Lett. 1997;112:47-55.
9. Berridge MV, Fraser JK, Carter JM, Lin FK. Effects of recombinant human erythropoietin on megakaryocytes and on platelet production in the rat. Blood. 1988;72:970-977.
10. Nagai A, Nakagawa E, Choi HB, Hatori K, Kobayashi S, Kim SU. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, oligodendrocytes grown in culture. J Neuropathol Expt Neurol. 2001;60:386-392.
11. Siren AL, Ehrenreich H. Erythropoietin-a novel concept for neuroprotection. Eur Arch Psychiatry Clin Neurosci. 2001;251:179-184.
12. Faulds D, Sorkin EM. Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anemia and the stimulation of erythropoiesis. Drugs. 1989;38:863-899.
13. Lappin T. The cellular biology of erythropoietin receptors. Oncologist. 2003;8(suppl 1):15-18.
14. Yu X, Lin CS, Costantini F, Noguchi CT. The human erythropoietin receptor gene rescues erythropoiesis and developmental defects in the erythropoietin receptor null mouse. Blood. 2001;98:475-477.
15. Raine AEG. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure implications of erythropoietin therapy. Lancet. 1988;I:97-100.
16. Shimada N, Saka S, Sekizuka K, Tanaka A, Takahashi Y, Nakamura T, Ebihara I, Koide H. Increased endothelin: nitric oxide ration is associated with erythropoietin-induced hypertension in hemodialysis patients. Ren Fail. 2003;25:569-578.
17. Ortho Biotech, Inc. PROCRIT 2004. Available at: www.rxlist.com/cgi/ generic/epoetin.htm. Accessed 2006.
18. Aranesp (darbepoetin alfa) [package insert]. Amgen: Thousand Oaks, Calif; 2006.
19. Lee JY, Tobian L, Hanlon S, Hamer R, Johnson MA, Iwai J. How is the NaCl signal transmitted in NaCl-induced hypertension? Hypertension. 1989;13:668-675.
20. Lee JY, Tobian L. Aqueduct block markedly reduces mortality and hypertension in post-DOCA Dahl R rats. Hypertension. 1991;17:1197-1203.
21. Lee JY. Expression of a cleavable fusion protein comprising a soluble human erythropoietin receptor protein fragment. US patent 5,843,726. 1998.
22. Lee JY. Purification of biologically active human erythropoietin-binding protein and detection of its binding sites. Ann Clin Lab Sci. 2007;37:63-70.
23. Smith DB, Johnson KS. Single-step purification of polypeptides expressed in Escherichia coli as fusion with glutathione S-transferase. Gene. 1988;67:31-40.
24. Sambrook J, Fritsch EF, Maniatis T, eds. Molecular Cloning. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989.
25. Mojon A, Fernandes JR, Hermida RC. Chronolab: an interactive software package for chronobiologic time series analysis written for the Macintosh computer. Chronobiol Intern. 1992;9:403-412.
26. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A. 1990;87:5978-5982.
27. Ammarguellat F, Llovera M, Kelly PA, Goffin V. Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells. Biochem Biophy Res Commun. 2001;284:1031-1038.
28. Ammarguellat F, Gogusev J, Drueke TB. Direct effect of erythropoietin on rat vascular smooth-muscle cell via a putative erythropoietin receptor. Nephrol Dial Transplant. 1996;11:687-692.
29. Wald M, Gutnisky A, Borda E, Sterin-Borda L. Erythropoietin modified the cardiac action of ouabain in chronically anaemic-uraemic rats. Nephron. 1995;71:190-196.
30. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int. 1999;55:808-820.
31. Juul S. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr. 2002;91(suppl):36-42.
32. Kawakami M, Sekiguchi M, Sato K, Kozaki S, Takahashi M. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J Biol Chem. 2001;276:39469-39475.
33. Means RT. Polycythemia vera. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, Wintrobe MM, eds. Wintrobe's Clinical Hematology. 10th ed. Baltimore, MD: Lippincott Williams & Wilkins; 1999:2374-2385.
34. Lage JMM, Panizo C, Masdeu J, Rocha E. Cyclist's doping associated with cerebral sinus thrombosis. Neurology. 2002;58:665.
35. Jones SJ, D'Andrea AD, Haines LL, Wong GG. Human erythropoietin receptor: cloning, expression, and biologic characterization. Blood. 1990;76:31-35.
36. Winkelmann JC, Penny LA, Deaven LL, Forget BG, Jenkins RB. The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p. Blood. 1990;76:24-30.
37. Kang DH, Yoon KI, Han DS. Acute effect of recombinant human erythropoietin on plasma levels of proendothelin-1 and endothelin-1 in haemodialysis patients. Nephrol Dial Transplant. 1998;13:2877-2883.
38. Lebel M, Lacasse-MS, Lariviere R, Kingma I, Grose JH. Plasma and blood vessel endothelin-1 concentrations in hypertensive uremic rats treated with erythropoietin. Clin Exp Hypertension. 1998;20:939-951.
39. Kusano E, Inoue M, Akai Y, Furuya H, Ando Y, Tabei K, Asano Y. Effect of ticlopidine hydrochloride on erythropoietin-induced rise in blood pressure in patients on maintenance hemodialysis. Nephron. 2002;91:654-658.
40. Casadevall M, Pique JM, Cirera I, Goldin E, Elizalde I, Panes J. Increased blood hemoglobin attenuates splanchnic vasodilation in portal-hypertensive rats by nitric oxide inactivation. Gastroenterol. 1996;110:1156-1165.
41. Wada Y, Matsuoka H, Tamai O, Kohno K, Okuda S, Imaizumi T. Erythropoietin impairs endothelium-dependent vasorelaxation through cyclooxygenase-dependent mechanisms in humans. Am J Hypertens. 1999;12:980-987.
42. Novak BL, Force RW, Mumford BT, Solbrig RM. Erythropoietin-induced hypertensive urgency in a patient with chronic renal insufficiency: case report and review of the literature. Pharmacotherapy. 2003;23:265-269.
43. Kuriyama S, Tomonari H, Tokudome G, Kaguchi Y, Hayashi H, Kobayash H, Horiguchi M, Ishikawa M, Hara Y, Hosoya T. Association of angiotensinogen gene polymorphism with erythropoietin-induced hypertension: a preliminary report. Hypertens Res Clin Exper. 2001;24:501-505.
44. Freudenthaler SM, Schreeb K, Korner T, Gleiter CH. Angiotensin II increases erythropoietin production in healthy human volunteers. Eur J Clin Invest. 1999;29:816-823.
45. Kim SW, Lee J, Kang DG, Jung K, Kim NH, Suh SP, Choi KC, Kang YJ. Erythropoietin does not affect nitric oxide system in rats with chronic renal failure. J Kor Med Sci. 2000;15:183-188.
46. Migliori M, Taccola D, Panichi V, De Pietro S, Andreini B, Di Benedetto A, Filippi C. Nitric oxide-dependent renal vasodilation is not altered in rat with rHuEpo-induced hypertension. Kidney Blood Press Res. 1999;22:140-145.
47. Zhou XJ, Pandian D, Wang XQ, Vaziri ND. Erythropoietin-induced hypertension in rats is not mediated by alterations of plasma endothelin, vasopressin, or arterial natriuretic peptide levels. J Am Soc Nephrol. 1997;8:901-905.
48. Urao N, Okigaki M, Yamada H, Aadachi Y, Matsuno K, Matsui A, Matsunaga S, Tateishi K, Nomura T, Takahashi T, Tatsumi T, Matsubara H. Erythropoietin- mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia [see comment]. Cir Res. 2006;98:1405-1413.
49. Sairanen T, Karjalainen-Lindsberg ML, Paetau A, Ijas P, Lindsberg PJ. Apoptosis dominant in the periinfarct area of human ischaemic stroke - a possible target of antiapoptotic treatments. Brain. 2006;129:189-199.
50. Knabe W, Siren AL, Ehrenreich H, Kuhn HJ. Expression patterns of erythropoietin and its receptor in the developing spinal cord and dorsal root ganglia. Anat Embryol. 2005;210:209-219.
51. Bahlmann FH, Song R, Boehm SM, Mengel M, von Wasielewski R, Lindschau C, Kirsch T, de Groot K, Laudeley R, Niemczyk E, Guler F, Menne J, Haller H, Fliser D. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation. 2004;110:1006-1012.
52. Maeda Y, Sakaguchi M, Naiki Y, Sumimoto Y, Miyatake J, Matsuda M, Hasegawa H, Kanamaru A. Possible involvement of soluble erythropoietin receptor in resistance to erythropoietin in patients with renal anemia. Am J Nephrol. 2001;21:426.
53. Shimizu R, Komatsu N, Miura Y. Dominant negative effect of a truncated erythropoietin receptor (EPOR-T) on erythropoietin-induced erythroid differentiation: possible involvement of EPOR-T in ineffective erythropoiesis of myeloblastic syndrome. Exp Hem. 1999;27:229-233.